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Abstract
Background and Aims: Vitamin D deficiency is more com-
mon in inflammatory bowel disease (IBD) patients than in 
the general population. However, there are conflicting data 
about predictive factors of vitamin D deficiency and its po-
tential association with disease activity. The aims of this 
study were to determine the prevalence and predictive fac-
tors of vitamin D deficiency and to evaluate a possible asso-
ciation with disease activity. Methods: A prospective obser-
vational study was conducted, including patients with IBD 
from January to July 2016. The Endocrine Society guidelines 
were considered for defining levels of serum 25-hydroxyvi-
tamin D (25-OH-D) as follows: deficient (< 20 ng/mL, < 10 ng/
mL being severe deficiency), insufficient (21–29 ng/mL), and 
adequate (> 30 ng/mL). Results: A total of 152 patients (52% 
men; 47.2 ± 17.3 years) were included, of whom 70% had 
Crohn’s disease (CD). Thirty-seven percent of patients were 
on immunosuppressors and 17% were on biologics. The ma-
jority were outpatients (88.2%). Mean 25-OH-D levels were 
17.1 ± 8 ng/mL (CD: 16.7 ± 8 ng/mL vs. ulcerative colitis: 17.6 
± 7 ng/mL, p = 0.1). Inadequate levels were present in 90.8% 
of patients (deficiency: 68.4%; insufficiency: 22.4%). A signif-
icant negative correlation between 25-OH-D levels and age 
(r = –0.2, p = 0.04), C-reactive protein (CRP) levels (r = –0.22, 
p = 0.004), and Harvey-Bradshaw index (HBi) (r = –0.32, p = 
0.001) was found. Patients with severe deficiency showed a 
higher CRP (0.6 vs. 1.4 mg/dL, p = 0.03), erythrocyte sedimen-
tation rate (ESR) (22 vs. 31 mm/h, p = 0.03), and HBi (2 vs. 5, 
p < 0.001) and lower hemoglobin (13.6 vs. 12.7 g/dL, p = 
0.02). There was no association between vitamin D deficien-
cy and gender, type, extent, and duration of disease, surgery, 
and other measures of disease activity, such as ESR, hemo-
globin (these 2 items except for severe deficiency), fecal cal-
protectin, or Truelove and Witts classification. Conclusions: 
There is a high prevalence of inadequate levels of vitamin D 
in IBD patients, particularly deficiency (68.4%). There seems 
to exist an association between lower levels of vitamin D and 
higher disease activity, especially in CD.
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Deficiência de vitamina D numa coorte de doentes 
Portugueses com doença inflamatória intestinal: 
prevalência e relação com a atividade da doença
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Resumo
Introdução: A deficiência de vitamina D é mais comum na 
doença inflamatória intestinal (DII) que na população geral. 
Contudo, existem dados controversos sobre fatores predi-
tivos da deficiência de vitamina D e a potencial associação 
com a atividade da doença. Os objetivos deste estudo 
foram determinar a prevalência e fatores preditivos da de-
ficiência de vitamina D e aferir possível associação à ativi-
dade da doença. Métodos: Desenhou-se um estudo obser-
vacional prospetivo incluindo doentes com DII entre janei-
ro e julho/2016. Foram consideradas as orientações da The 
Endocrine Society para definir níveis de 25-hidroxivitamina 
D (25-OH-D) sérica como: deficientes (< 20 ng/mL, sendo  
<10 ng/mL deficiência grave [DG]), insuficientes (21–29 ng/
mL) e adequados (> 30 ng/mL). Resultados: Foram incluí-
dos 152 doentes (52% homens; 47.2 ± 17.3 anos), dos quais 
70% com Doença de Crohn (DC). Do total, 37% estavam 
medicados com immunossupressores e 17% com biológi-
cos. A maioria (88.2%) estava em ambulatório. O nível sérico 
de 25-OH-D foi 17.1 ± 8 ng/mL (DC: 16.7 ± 8 ng/mL vs. Colite 
ulcerosa: 17.6 ± 7 ng/mL, p = 0.1). Verificaram-se níveis in-
adequados em 90.8% (deficiência: 68.4%; insuficiência: 
22.4%). Registou-se correlação negativa significativa entre 
níveis de 25-OH-D e idade (r = –0.2, p = 0.04), proteína  
C-reativa (PCR) (r = –0.22, p = 0.004) e índice Harvey-Brad-
shaw (iHB) (r = –0.32, p = 0.001). Doentes com DG apresen-
taram níveis mais elevados de PCR (0.6 vs. 1.4 mg/dL, p = 
0.03), velocidade de sedimentação (VS) (22 vs. 31 mm/h,  
p = 0.03) e iHB (2 vs. 5, p < 0.001), e mais baixos de hemo-
globina (13.6 vs. 12.7 g/dL, p = 0.02). Não se verificou asso-
ciação entre deficiência de vitamina D e sexo, tipo, extensão 
e duração da doença, cirurgia, e outras medidas de ativi-
dade da doença como VS, hemoglobina (estas duas exceto 
para DG), calprotectina fecal ou classificação Truelove e 
Witts. Conclusões: Registou-se prevalência alta de níveis in-
adequados de vitamina D na DII, particularmente de defi-
ciência (68.4%). Parece existir associação entre níveis mais 
baixos de vitamina D e maior atividade da doença, nome-
adamente na DC. © 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Vitamin D deficiency has become an increasingly rel-
evant topic in medical practice and literature, particu-
larly during the last years, and since 2010 more than one 
thousand papers subordinated to this subject have been 
published and indexed in PubMed per year. A high prev-
alence of vitamin D deficiency has been reported not 
only in sick populations [1], particularly hospitalized pa-
tients, but also in healthy individuals, as demonstrated 
in a recent study that defines it as being pandemic in 
Europe [2]. A contemporary study [3], performed in the 
north of Portugal, in 2016, reported a prevalence of 48 
and 74% of vitamin D deficiency in a healthy adult pop-
ulation (18–67 years), in summer and winter, respective-
ly. There is evidence of an association between lower lev-
els of vitamin D and higher risk of numerous diseases, 
such as cancer, mental disorders, infection, cardiovascu-
lar diseases, type 2 diabetes mellitus, and autoimmune 
disorders [4].
Inflammatory bowel disease (IBD) refers to a group 
of chronic autoimmune diseases, consisting mainly of 
Crohn’s disease (CD) and ulcerative colitis (UC), which 
involve a dysregulation of the immune system with con-
sequences in the intestinal wall [5]. Vitamin D deficien-
cy has also been reported in these patients, although 
published data are conflicting as the prevalence of vita-
min D deficiency in patients with IBD ranges from 16 to 
95% [6–14]. It is also not clear in which type of IBD the 
prevalence of vitamin D deficiency is higher [8, 15]. Fac-
ing the need to clarify this controversy, a systematic re-
view with a meta-analysis was conducted in 2015. It in-
cluded 14 studies with a total of 1,891 patients and re-
ported that patients with IBD had 64% higher odds of 
vitamin D deficiency when compared with controls [15]. 
An association with disease activity has been described 
more inconsistently, with some authors arguing that 
there is a relation between lower levels of vitamin D and 
higher disease activity [6, 16–21], while others have not 
found any relation [22–24]. There are 2 published Por-
tuguese studies on this subject, both from the north of 
the country. Castro et al. [6] encountered a prevalence of 
vitamin D deficiency of 30% (samples were collected in 
the summer and patients included were only in ambula-
tory care) in a cohort of 76 patients with IBD, particu-
larly in those with CD, and found a correlation between 
lower levels of vitamin D and higher disease activity and 
worse quality of life. Santos-Antunes et al. [7] included 
68 patients with IBD with indication to start anti-TNF 
therapy and found a prevalence of vitamin D deficiency 
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of 93%. The Endocrine Society guidelines recommend 
vitamin D screening only in high-risk individuals, where 
IBD patients are included [1].
The aim of this study was to determine the prevalence 
of vitamin D deficiency in a cohort of Portuguese IBD 
patients and identify whether there was an association be-
tween vitamin D levels and disease activity or not.
Methods
A prospective observational and cross-sectional study was per-
formed in a district Hospital in the region of Lisbon between Janu-
ary and July 2016. Winter was considered from December to April 
and summer from May to July.
Inclusion and Exclusion Criteria 
Patients aged 18 years and older with a diagnosis of IBD ac-
cording to ECCO guidelines [25, 26] were consecutively included; 
either they were in an ambulatory setting or hospitalized. Exclu-
sion criteria included medical conditions that interfere with vita-
min D levels, such as chronic kidney disease, liver cirrhosis, exo-
crine pancreatic insufficiency, pregnancy, lactation, the use of 
medications, such as anticonvulsants, and supplements with vita-
min D.
Demographic and Clinical Variables 
Demographic and clinical data were collected by interview and 
included age, gender, type, extent, location, and behavior of the 
disease according to the Montreal Classification [25, 26], duration 
of disease, IBD-related surgeries, actual hospitalization or ambula-
tory care, and medication for IBD.
Vitamin D and Laboratory Variables
All samples were collected and analyzed at the Hospital Central 
Laboratory. Vitamin D was assessed by the serum 25-hydroxyvi-
tamin D (25-OH-D) through the LIAISON® 25 OH Vitamin D 
Assay which is a chemiluminescent immunoassay. 
Categorization of Vitamin D Levels 
The Endocrine Society guidelines [1] were considered for eval-
uating the levels of 25-OH-D: deficiency (< 20 ng/mL, < 10 ng/mL 
being a severe deficiency), insufficiency (21–29 ng/mL), and ade-
quacy (> 30 ng/mL). Inadequacy includes deficiency and insuffi-
ciency.
Definition of Disease Activity
Disease activity was measured both clinically and analytically. 
The clinical indices used in the study were the Truelove and Witts 
classification (TLWc) for UC and the Harvey-Bradshaw index 
(HBi) for CD. According to the TLWc, UC was classified as inac-
tive, mild, moderate, and severe. A score of the HBi > 4 was con-
sidered as active disease. Laboratory markers of disease activity 
were measured by C-reactive protein (CRP; normal range < 0.29 
mg/dL), erythrocyte sedimentation rate (ESR; normal range < 20 
mm/h), hemoglobin (Hb; normal range for men < 13 g/dL and for 
women < 12 g/dL), and fecal calprotectin (FC; normal range <100 
μg/g).
Endpoints
Our primary endpoints were to determine the prevalence of 
vitamin D deficiency and to evaluate an association between vita-
min D levels and disease activity. Our secondary endpoint was to 
analyze if there were predictors of vitamin D deficiency.
Data and Statistical Analysis
Normally distributed variables were described using the mean 
and standard deviation; variables with a skewed distribution were 
described using the median and range. Crude associations between 
pairs of variables were analyzed using the Student t test and the χ2 
test. Nonparametric tests (Mann-Whitney U test) were used when 
normality could not be assumed. All tests were two-sided. p values 
< 0.05 were considered statistically significant. We did not perform 
any correction for multiple testing because we considered our 
analyses explorative. IBM SPSS Statistics for Windows version 20.0 
(IBM Corp., Armonk, NY, USA, released in 2011) was used for all 
statistical analyses.
Ethical Considerations
The study was approved by the Institutional Ethics Committee 
of our hospital. All patients signed an informed consent form.
Results
Demographic and Clinical Data
A total of 152 patients were included in the study, of 
whom 79 (52%) were male and the median age was 47.2 ± 
17.3 years (range 17–89). Of these, 106 (70%) had CD, 44 
(29%) UC, and 2 (1%) unclassified IBD, with a mean dis-
ease duration of 8.4 ± 7.9 years (range 0–45). About one-
third of patients (37%, 55 patients) were medicated with 
immunosuppressors (azathioprine or methotrexate), 17% 
(26 patients) with anti-TNF, which were either infliximab 
or adalimumab, and 9% (14 patients) were on combina-
tion therapy with azathioprine (9 under infliximab and 5 
under adalimumab). There were 17% (26 patients) medi-
cated with corticosteroids and 78.3% (119 patients) with 
salicylates. A minority of patients (11.8%, 18 patients) was 
hospitalized. Of CD patients, 92 (86.2%) had small bowel 
involvement, with 51 (48.1%) of them showing ileocolic 
involvement (L3 according to the Montreal Classifica-
tion), 22 patients (20.8%) had perianal disease, and 33 
(21.7%) had had small bowel resection. Of UC patients, 18 
(40.8%) had pancolitis (E3 according to the Montreal 
Classification). More detailed information about demo-
graphic and clinical data is displayed in Table 1.
Prevalence of Vitamin D Deficiency and Vitamin D 
Levels
Mean vitamin D levels were 17.1 ± 8 ng/mL, slightly 
higher in UC (17.6 ± 7 ng/mL) than in CD (16.7 ± 8 ng/
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mL); this difference was not statistically significant (p = 
0.1). Globally, the prevalence of vitamin D deficiency was 
68.4% and was higher in CD (72%) than in UC (65%), but 
this difference was not statistically significant (p = 0.4). 
Taking all patients into consideration, 17.7% had severe 
deficiency, and this prevalence tended to be significantly 
higher in CD (24%) than in UC (11%, p = 0.06). Inade-
quate levels of vitamin D were present in 90.8% of pa-
tients, a percentage very similar in CD and UC (91 vs. 
93%, respectively, p = 1). More detailed information 
about the prevalence of inadequate vitamin D levels can 
be found in Table 2.
Vitamin D Deficiency and Disease Activity
The influence of vitamin D levels on disease activity 
was evaluated numerically and categorically. According 
to the clinical indices, there were 47 patients (30.9%) with 
active disease, of whom 30 had CD. In UC, 36.9% had ac-
tive disease (88.2% had mild or moderate activity), and in 
CD 28.3% had a HBi compatible with active disease. Con-
sidering this clinical definition of active disease, there was 
no association between active disease and vitamin D de-
ficiency (p = 1); however, patients with active disease 
more frequently had severe vitamin D deficiency than 
those in remission (33 vs. 13%, p = 0.004).
Patients with vitamin D deficiency more commonly 
had markers of higher disease activity than patients with-
out vitamin D deficiency, except for FC. They had more 
active disease determined by the TLWc (65 vs. 62%, p = 
0.4) or the HBi (2.8 vs. 2.5, p = 0.6), higher CRP levels 
(0.85 vs. 0.53 mg/dL, p = 0.3) and ESR (24.9 vs. 22.4 
mm/h, p = 0.5), and lower Hb levels (13.3 vs. 13.6 g/dL, 
p = 0.4), although these differences were not statistically 
significant. Nonetheless, when considering patients with 
severe vitamin D deficiency, these differences were all 
statistically significant, except for the TLWc: they also 
had more active disease determined by the TLWc (12 vs. 
7%, p = 0.07) or the HBi (5 vs. 2, p = 0.001), higher CRP 
levels (1.4 vs. 0.6 mg/dL, p = 0.03) and ESR (31 vs. 22 
mm/h, p = 0.03), and lower Hb levels (12.7 vs. 13.6 g/dL, 
p = 0.02).
It was possible to determine correlations between lev-
els of vitamin D and some demographic, clinical, and an-
alytical variables. Patients with lower levels of vitamin D 
were significantly older (r = –0.20, p = 0.04) and had a 
higher HBi (r = –0.32, p = 0.001) and CRP levels (r = 
–0.22, p = 0.004). More detailed information about the 
relation between vitamin D deficiency and disease activ-
ity is presented in Table 3.
Table 1. Baseline characteristics of patients: demographic, clini-
cal, and laboratorial data (n = 152)
Age, years 47.2±17.3 (17–89)
Male sex 79 (52)
Type of disease
Crohn disease 106 (70)
Ulcerative colitis 44 (29)





















C-reactive protein, mg/dL 0.75±1.8
Sedimentation rate, mm/h 24.1±23
Hemoglobin, g/dL 13.4±1.8
Fecal calprotectin, mg/kg 728±1200
Harvey-Bradshaw index 2.7±3
Truelove and Witts, mild/moderate/severe 7/8/2
Values are means ± standard deviations (ranges) or n (%) un-
less otherwise indicated. a According to the Montreal Classifica-
tion.
Table 2. Prevalence of inadequate vitamin D levels
Total CD UC p value
Inadequate levels 90.8 91 93 1
Insufficiency 22.4 20 28 0.3
Deficiency 68.4 72 65 0.4
Severe deficiency 17.7 24 11 0.06
Values are %. CD, Crohn’s disease; UC, ulcerative colitis.
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Predictors of Vitamin D Deficiency and Severe 
Deficiency
There were no statistically significant differences in re-
lation to baseline demographic and clinical characteris-
tics and medication of patients with and without vitamin 
D deficiency except for the use of corticosteroids, which 
was more common in patients with vitamin D deficiency 
(85 vs. 65%, p = 0.04), and the season when vitamin D 
deficiency was diagnosed, with winter being the most fre-
quent one (78 vs. 57%, p = 0.005).
When considering patients with severe deficiency of 
vitamin D, more pronounced differences were noticed. 
Apart from a diagnosis during the winter and the use of 
corticosteroids also being more frequent in these patients 
(27 vs. 10%, p = 0.008 and 33 vs. 15%, p = 0.05, respec-
tively), other differences were noticed. Patients on biolog-
ics more often had severe deficiency than patients who 
were not under this medication (37 vs. 16%, p = 0.01), and 
inpatients more commonly had severe deficiency than 
outpatients (50 vs. 15%, p = 0.001). There were 2 other 
differences, although they were not statistically signifi-
cant, namely that patients with CD more frequently had 
a severe deficiency (24 vs. 11% of UC patients, p = 0.06) 
and patients with an age above 60 years also had more 
severe deficiency than patients under 60 years (30 vs. 
17%, p = 0.07). More detailed information about predic-
tors of vitamin D deficiency is presented in Table 4.
Discussion
The prevalence of vitamin D deficiency is high and is 
considered a public health problem since it has implica-
tions in many diseases, besides the well-known conse-
quences on bone disease. Vitamin D, or calciferol, is a 
generic term and refers to a group of lipid-soluble com-
pounds, 25-OH-D being the major circulating form of 
vitamin D and 1,25-dihydroxyvitamin D (1,25[OH]2D) 
its most active form [27]. Vitamin D has a well-known 
role in mineral metabolism and bone health, and its sup-
plementation in young children is well established for 
preventing rickets [28]. In the last decade, the perspective 
on the influence of vitamin D on health has changed due 
to the discovery of vitamin D receptor and vitamin D ac-
tivating enzyme 1-α-hydroxylase (CYP27B1) in many 
cell types, such as the intestine, pancreas, prostate, and 
immune system [29, 30]. Specifically, in immunology, 
the synthesis of 1,25(OH)2D by immune cells and pe-
ripheral tissues has been proposed to have immunomod-
ulatory properties similar to locally active cytokines [31, 
32].
Vitamin D deficiency has been reported to be very 
prevalent among patients with IBD. Although a high 
prevalence of vitamin D deficiency is also being described 
in the general population, it seems to be higher in patients 
with IBD, with a calculated odds ratio of 1.64 [15]. In fact, 
different prevalence rates of vitamin D deficiency were 
published, namely 16–95% [6–14], but the later studies, 
which include a systematic review [15], reported high 
prevalence rates. Our study is in accordance with the 
most recent data, revealing a prevalence of 68% of vita-
min D deficiency, and almost one-fifth of patients had a 
severe deficiency, with only around 9% of patients having 
adequate levels of vitamin D. In comparison with the 2 
published Portuguese studies [6, 7], this prevalence lies in 
between, which can be explained by the differences in the 
inclusion criteria: our study included patients with IBD 
in different clinical settings, while one of the studies in-
cluded just outpatients [6] and the other included only 
patients with more severe disease [7].
Table 3. Influence of markers of disease activity on vitamin D deficiency and severe deficiency
Deficiency p value Severe deficiency p value
no yes no yes
Mean CRP, mg/dL 0.53 0.85 0.3 0.6 1.4 0.03
Mean ESR, mm/h 22.4 24.9 0.5 22 31 0.03
Mean Hb, g/dL 13.6 13.3 0.4 13.6 12.7 0.02
Mean FC, mg/kg 1,117 556 0.02 754 598 0.4
Mean HBi 2.5 2.8 0.6 2 5 0.001
TLWc (inactive vs. active) 62% 65% 0.4 7% 12% 0.07
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; FC, fecal calprotectin; HBi, 
Harvey-Bradshaw index; TLWc, Truelove and Witts classification.
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The mean values of vitamin D assessed in our study, 
17.1 ± 8 ng/mL, were classified as deficient. A relevant 
question that is being raised in several recent papers is 
whether we are overdiagnosing vitamin D deficiency. 
Even among healthy individuals, the prevalence of vita-
min D deficiency is so high that it has been referred to as 
pandemic in Europe and North America [2, 33, 34]. Some 
of the factors that may contribute to this high prevalence 
in heathy individuals in different studies are seasonality, 
differences in the analytical method to measure vitamin 
D, heterogeneous populations included in the studies 
(sex, life stage/age, and ethnicity), and different cutoffs 
for defining deficiency. It is interesting to note that, over 
the last 2 decades, the recommended cutoff values and 
recommended diary intake of vitamin D to reach an ad-
equate level have changed to higher values [33]. The rea-
son for this is probably related to the great amount of 
studies reporting an increased prevalence of vitamin D 
deficiency in several diseases, including IBD [10, 33].
IBD patients are at risk of vitamin D deficiency, and 
many factors are likely to contribute, such as malabsorp-
tion, reduced sunlight exposure, insufficient physical ac-
tivity, low vitamin D intake, smoking, and corticoid use 
[8]. Among the described factors, this study supports 2 of 
them as factors that can predispose to vitamin D defi-
ciency, namely reduced sunlight exposure and corticoid 
use.
There was a tendency towards a difference in the 
prevalence of vitamin D deficiency between CD and 
UC. When analyzing all patients with deficiency, the 
difference was small (72% of deficiency in CD and 65% 
in UC, p = 0.4), but when the subset of patients with se-
vere deficiency was analyzed, this difference was con-
siderable, although not statistically significant, severe 
deficiency being more frequent in CD patients than in 
UC patients (24% in CD vs. 11% in UC, p = 0.06). In 
contrast to our findings, the largest meta-analysis on 
this topic reported a higher odds ratio for vitamin D de-
ficiency in UC than in CD (2.24 and 1.63, respectively), 
although the authors assume that this could be, at least 
in part, due to a sample size effect, because there were 
fewer total patients and fewer events in the UC meta-
analysis than in the CD meta-analysis [15]. A relation to 
disease activity could not be determined due to a lack of 
this information in the majority of the studies included 
in this meta-analysis.
One of the most interesting observations in this study 










>60 years 69 0.8 17 0.07
<60 years 72 30
Gender
Female 71 0.4 22 0.4
Male 66 18
Season
Winter 78 0.005 27 0.008
Summer 57 10
Type of disease
Crohn disease 69 0.9 24 0.06
Ulcerative colitis 68 11
Hospital setting
Inpatients 72 0.8 50 0.001
Outpatients 68 15
Surgery
Yes 66 0.8 24 0.4
No 69 19
Current medication, yes/no
Immunosuppressors 63/71 0.4 19/20 0.9
Biologics 76/67 0.5 37/16 0.01
Corticosteroids 85/65 0.04 33/15 0.05
Table 4. Influence of demographic and 
clinical variables on vitamin D deficiency 
and severe deficiency
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creased disease activity, measured in different ways 
(both clinical and laboratorial), a finding that has not 
been so clearly established in most of the studies. The 
high prevalence of vitamin D deficiency could hinder 
identification of possible predictive factors and a rela-
tion with disease activity. Consequently, analyses of as-
sociations with lower levels of vitamin D were conduct-
ed in a numeric and a categorical way (the latter using 
the definition of severe deficiency). We found that low-
er levels of vitamin D were associated with older age, 
higher CRP levels, and a higher HBi. In those patients 
fitting the category of severe deficiency, it was noted 
that they more frequently presented the following char-
acteristics: active disease, when measured by clinical in-
dices, higher ESR and lower Hb levels, use of biologics 
or corticosteroids, and being hospitalized. These results 
suggest that low levels of vitamin D are linked to high 
disease activity. There is no consensus on this issue in 
the literature, although many studies have already re-
ported a relation between low levels of vitamin D and 
more clinical activity [6, 16–21], while others have not 
[22–24]. This relation is more consistently reproduced 
when activity is subjectively measured, by clinical indi-
ces, than when activity is objectively measured, by sys-
temic inflammation markers, such as CRP or ESR (as 
fecal calprotectin is measured in almost none of the 
studies). For example, in CD, many studies report a link 
between vitamin D deficiency and increased clinical ac-
tivity, either measured by the HBi [8, 16, 21] or Crohn’s 
Disease Activity Index [17, 18]. In UC, data are more 
scarce, and, until now, only 2 studies reported an in-
verse relation between vitamin D levels and disease ac-
tivity, measured by clinical scores [21, 34]. The relation 
with systemic inflammation is not that linear, presum-
ably because even patients with active disease can have 
normal CRP values [18], and very seldom have higher 
CRP levels been associated with vitamin D deficiency 
[22] and insufficiency [6]. To the best of our knowledge, 
there are no studies about the relation between ESR and 
anemia and severe vitamin D deficiency. Possible expla-
nations are that only a few studies measured those vari-
ables (or at least referred to them), and there was a rela-
tively high proportion of patients with active disease in 
our study (around one-third of the total). In our study, 
FC was not associated with vitamin D deficiency. FC is 
a sensitive (60–70%) and specific marker of active dis-
ease, better than CRP [25]. We assume that this lack of 
relation is associated with the fact that median levels of 
FC were high in our study (298 μg/g, n = 105), and as 
the prevalence of deficiency was also high, it was statis-
tically more difficult to establish an association. The 
study by Kabbani et al. [21] including 965 patients also 
associated low vitamin D levels with a higher need of 
biologics, corticosteroids, and hospitalizations, and we 
obtained a similar finding, namely that patients with 
these characteristics more commonly had severe vita-
min D deficiency.
Other strengths of our study were the number of in-
cluded patients, the highest until now in a Portuguese 
population and one of the highest in unicentric studies, 
and the fact that patients were included in a prospective 
way. Also, this is the first study performed in the south of 
the country.
There are limitations to our investigation. We includ-
ed a heterogenic group of patients, incorporating CD and 
UC patients, with a wide range of age, and hospitalized 
and ambulatory patients, which, on the one hand, could 
improve the analysis but, on the other hand, could result 
in many confounders, which we tried to diminish by ana-
lyzing some subgroups of patients. Another limitation is 
the fact that we measured vitamin D levels both in sum-
mer and winter, and, as expected, there was a statistically 
significant difference in the levels between the 2 seasons, 
demonstrating the importance of seasonality for vitamin 
D biology.
There are already some studies which report that sup-
plementation with vitamin D could have good outcomes, 
although these effects have been measured by symptoms 
and have not been demonstrated by laboratory markers 
or endoscopy [35–39]. Also, the exact supplementation 
dose of vitamin D has not yet been determined. Routine 
screening is not yet recommended in European guide-
lines unless there is suspicion of bone disease or pro-
longed corticosteroid use [40].
Conclusions
Vitamin D deficiency is very prevalent in Portuguese 
IBD patients, in CD as well as in UC patients. Winter and 
corticosteroid medication are predictors of vitamin D de-
ficiency. In addition, hospitalization and biologics medi-
cation are predictors of severe vitamin D deficiency. It is 
important to determine the level of deficiency of vitamin 
D, because the lower the level of vitamin D, the more ev-
ident the link to higher disease activity, especially in CD 
patients. Future research should focus on the potential 
therapeutic effect of vitamin D supplementation.
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